Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3556 - Neurological benefit of BRAF-inhibition and MEK-inhibition in patients with brain metastases from BRAF-mutated melanoma


09 Oct 2016


Poster display


Marnix Geukes Foppen


Annals of Oncology (2016) 27 (6): 379-400. 10.1093/annonc/mdw379


M. Geukes Foppen1, W. Boogerd2, C.U. Blank1, J.B.A.G. Haanen1, J.V. van Thienen1, D. Brandsma1

Author affiliations

  • 1 Medical Oncology, The Netherlands Cancer Institute, 1066 CX - Amsterdam/NL
  • 2 Neuro-oncology, The Netherlands Cancer Institute, Amsterdam/NL


Abstract 3556


Patients (pts) with brain metastases (BM) from melanoma have a median survival of 2 to 6 months after whole brain radiotherapy. Targeted therapy (TT) improves OS in pts with BRAF-mutated metastatic melanoma. In this retrospective analysis we investigated response, neurological benefit and survival in pts with BM from BRAF-mutated melanoma treated with TT.


We analysed 147 pts diagnosed with BM from BRAF-mutated melanoma between 2010 and 2016 treated at the Netherlands Cancer Institute. Pts either received vemurafenib, dabrafenib, or the combination of vemurafenib/cobimetinib or dabrafenib/trametinib. Neurological symptoms were scored before treatment and every 4 weeks until cessation of therapy. Response was assessed with MRI brain and CT thorax/abdomen after 8 weeks. Kaplan-Meier analyses were used to estimate PFS and OS.


Median OS of all pts was 6.6 months (mo) (95%CI 5.7–7.4). Median intracranial PFS of all pts was 4.2 mo (95%CI 3.3–5.2). Sixty-three pts (43%) had symptomatic BM (sBM) before start of TT and had a median intracranial PFS of 3.7 mo (95%CI 2.7–4.7). The intracranial radiological response rate (RRR: stable disease/partial or complete response) was 63% versus extracranial 68%. Twenty-nine pts with sBM showed a clinical neurological response (46%), 13 were stable (21%), 16 progressive (25%) and 5 were not evaluable (8%). Pts with improving or stable neurological symptoms had a significantly better OS compared to pts with worsening symptoms; 8.8 vs 4.4 mo (p


Intracranial response parallels systemic response in pts with brain-metastasized melanoma treated with TT. TT improves neurological symptoms in about half of the pts with sBM from BRAF-mutated melanoma.

Clinical trial identification

Legal entity responsible for the study

Netherlands Cancer Institute


Netherlands Cancer Institute


C. Blank: Advisory role for Novartis, Roche/Genentech, MSD, GlaxoSmithKline, Bristol Myers Squibb, Pfizer and Lilly Grants from Novartis. J.B.A.G. Haanen: Grants from MSD, grants from Bristol-Myers-Squibb, and grants from GlaxoSmithKline Consulting or advisory role for MSD Oncology, Pfizer, Bristol-Myers-Squibb, Novartis, Neon Therapeutics and Roche/Genentech. J.V. van Thienen: Advisory board/consultancy voor MSD en BMS. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings